The Lancet Regional Health: Western Pacific最新文献

{"title":"NHIS vs. Big Tobacco: South Korea’s pursuit of cost recovery through litigation","authors":"Katelyn J. Yoo , Neil W. Schluger","doi":"10.1016/j.lanwpc.2025.101655","DOIUrl":"10.1016/j.lanwpc.2025.101655","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101655"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144771437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of tuberculosis infection with the development of active tuberculosis and comorbidities in rural China: a 10-year follow-up results of a population-based, multicentre, prospective study","authors":"Henan Xin , Jiang Du , Xuefang Cao , Weitao Duan , Aiwei He , Jun Liang , Limei Zhu , Boxuan Feng , Yijun He , Lingyu Shen , Juanjuan Huang , Zisen Liu , Fang Liu , Shumin Yang , Zuhui Xu , Cheng Chen , Bin Zhang , Jiaoxia Yan , Yanchun Liang , Rong Liu , Lei Gao","doi":"10.1016/j.lanwpc.2025.101659","DOIUrl":"10.1016/j.lanwpc.2025.101659","url":null,"abstract":"<div><h3>Background</h3><div>In China, there is limited research on the role of recent and long-term infection of <em>Mycobacterium tuberculosis</em> in relation to the incidence of pulmonary tuberculosis (PTB), as well as the impact of tuberculosis infection (TBI) on other diseases. A population-based, multicenter prospective study (LATENTTB-NSTM) was implemented since 2013 to assess the prevalence of TBI and to track the development of active disease in rural China. This cohort study provides an opportunity to address these gaps in knowledge.</div></div><div><h3>Methods</h3><div>In October 2023, all 21,832 participants from rural China who initially participated in the baseline survey of the LATENTTB-NSTM study were invited to take part in the 10-year follow-up survey. The data on the incident PTB and other health concerns including type 2 diabetes mellitus (T2DM), cancers, cardiovascular and cerebrovascular diseases were acquired from medical record or self-reported. The proportion of baseline TBI and newly acquired infection to the incident PTB and the association of baseline TBI status with the incidence of other diseases were analyzed.</div></div><div><h3>Findings</h3><div>Overall, 21,211 study participants with a sum of 170,152 person-years were included in final analysis. During the 10-year period, a total of 181 incident PTB patients were identified, including 134 patients developed from TBI defined at baseline and 47 patients developed from newly acquired infection during follow-up. The proportion of newly acquired infection during follow-up was statistically pronounced in incident PTB cases diagnosed in the latter 5 years as compared to in the first 5 years of the follow-up period (38·30% (18/47) vs. 21·64% (29/134), p = 0·031). The proportion of baseline TBI was statistically higher in incident PTB cases aged ≥60 years than in those aged <60 years (85·19% (69/81) vs. 65·00% (65/100), p = 0·002). In addition, baseline TBI status was found to be significantly associated with increased risk of incident T2DM, cancers and chronic bronchitis with adjusted hazard ratio of 1·22 (95% confidence interval (CI): 1·04–1·42), 1·81 (95% CI: 1·20–2·72), and 2·94 (95% CI: 1·06–8·15), respectively. The risk of incident T2DM slightly increased along with the increasing intensity of the immune response in TBI testing at baseline.</div></div><div><h3>Interpretation</h3><div>As compared to recent infection, TBI remains the dominating contributor of incident PTB in rural China. Alongside efforts to systematically manage infectious cases and close contacts, preventive treatment targeting individuals under high risk of developing active diseases from TBI is crucial for achieving rapid declining of PTB incidence. Moreover, the possible influence of TBI on the other health conditions further underscores the importance of TBI management from a new perspective.</div></div><div><h3>Funding</h3><div>The <span>CAMS Innovation Fund</span> for Medical Sciences and ","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101659"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144830182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort","authors":"Fanghui Zhao ,&nbsp;Qi Chen ,&nbsp;Chao Zhao ,&nbsp;Lingling Nie ,&nbsp;Shangying Hu ,&nbsp;Jian Yin ,&nbsp;Lingxian Qiu ,&nbsp;Zhaofeng Bi ,&nbsp;Jiali Quan ,&nbsp;Yufei Li ,&nbsp;Mingzhu Li ,&nbsp;Xun Zhang ,&nbsp;Qinjing Pan ,&nbsp;Caihong Li ,&nbsp;Lidong Ke ,&nbsp;Xiaoli Liu ,&nbsp;Fengxian Zheng ,&nbsp;Cuihong Dai ,&nbsp;Zhe Wang ,&nbsp;Xuefeng Kuang ,&nbsp;Ningshao Xia","doi":"10.1016/j.lanwpc.2025.101668","DOIUrl":"10.1016/j.lanwpc.2025.101668","url":null,"abstract":"<div><h3>Background</h3><div>A safe and highly efficacious <em>Escherichia coli</em>-produced HPV-16/18 bivalent vaccine (Cecolin®) offers a cost-effective cervical cancer prevention measure. Here, we report data on the long-term efficacy and immunopersistence up to 10 years post-vaccination.</div></div><div><h3>Methods</h3><div>In the Phase III clinical trial (<span><span>NCT01735006</span><svg><path></path></svg></span>), 7372 women were enrolled and randomly assigned to receive the HPV or control vaccine (hepatitis E vaccine). Women from 2 sites (Xinmi City and Fengning County; N = 1986) were invited to participate in the extension study. Cervical samples were collected for ThinPrep Pap tests and HPV DNA testing. Serum samples from participants in the immune persistent subcohort (N = 300) were collected for neutralising antibody testing. The co-primary outcomes were high-grade cervical, vulvar or vaginal lesions and persistent infection (over 6 months) associated with HPV 16/18 in the per-protocol population.</div></div><div><h3>Findings</h3><div>A total of 1648 women participated in the extension study (806 from the vaccine group and 842 from the control group). Over a median 10.2-year follow-up, vaccine efficacy was 87.5% (95% CI 6.4–99.7) against high-grade cervical, vulvar or vaginal lesions (1 case in the vaccine group and 8 cases in the control group, <em>P</em> = 0.0391), and 97.0% (95% CI 78.9–100.0) against persistent infection (over 6 months, 1 case in the vaccine group and 32 cases in the control group, <em>P</em> &lt; 0.0001) in the per-protocol population. The GMCs of neutralising antibodies peaked by month 7, declined through month 42, with HPV-16 plateauing and HPV-18 continuing to decline thereafter. At 114 months, 98.9% (93/94) of baseline seronegative participants remained seropositive for HPV-16 with the GMC of 61.84 IU/mL and 97.0% (98/101) remained seropositive for HPV-18 with the GMC of 18.73 IU/mL.</div></div><div><h3>Interpretation</h3><div>The <em>E. coli</em>-produced HPV 16/18 bivalent vaccine elicits sustained antibody responses and confers durable protection against HPV 16/18 associated high-grade cervical, vulvar or vaginal lesions and persistent infections for a minimum of 10 years post-vaccination.</div></div><div><h3>Funding</h3><div><span>National Key Research and Development Program of China</span> (<span><span>2023YFC2307602</span></span>), <span>National Natural Science Foundation of China</span> (<span><span>823B2086</span></span>, <span><span>82273640</span></span>), <span>Beijing Natural Science Foundation</span> (<span><span>L244091</span></span>), and <span>Fundamental Research Funds for the Central Universities</span> (<span><span>20720220005</span></span>).</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101668"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The silent exclusion: rethinking eligibility and generalizability in clinical trials","authors":"Jens-Ulrik Jensen ,&nbsp;Niklas Dyrby Johansen ,&nbsp;Alexander G. Mathioudakis ,&nbsp;Tor Biering-Sørensen ,&nbsp;Pradeesh Sivapalan","doi":"10.1016/j.lanwpc.2025.101605","DOIUrl":"10.1016/j.lanwpc.2025.101605","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101605"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promoting meaningful participation of individuals with lived experience of mental health conditions in China","authors":"Hao Yao","doi":"10.1016/j.lanwpc.2025.101593","DOIUrl":"10.1016/j.lanwpc.2025.101593","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101593"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144911684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of genetics and the environment on cancer risk in Indigenous Australians: a narrative review","authors":"Andrew D.K. Nguyen ,&nbsp;Katie Meehan ,&nbsp;Andrew D. Redfern ,&nbsp;Alex Brown ,&nbsp;Melanie Robinson ,&nbsp;Lenny Papertalk ,&nbsp;Sandra C. Thompson","doi":"10.1016/j.lanwpc.2025.101627","DOIUrl":"10.1016/j.lanwpc.2025.101627","url":null,"abstract":"<div><div>Aboriginal and Torres Strait Islander (hereafter respectfully named Indigenous) Australians are diagnosed with some cancers substantially more frequently than non-Indigenous Australians implying a different risk factor landscape. Additionally, poorer outcomes for certain cancers are exacerbated by lower cancer screening rates and later diagnoses compared to non-Indigenous Australians. An improved understanding of cancer causation would allow better shaping and targeting of screening programs for those at the highest risk. A narrative review of relevant environmental and genetic risk factors for various cancers in Indigenous populations was undertaken. Research databases were interrogated in June 2024, with information extracted. Further peer-reviewed and grey literature was identified by specific searchers and citation snowballing. The results show that many distinct risk factors exist in environmental, sociocultural, educational, behavioural and metabolic domains; these complex and frequently interacting risks include direct and indirect social and cultural factors. Identified gaps include limited published literature on the genetic determinants of cancer, decreased levels of effective cancer surveillance for Indigenous Australians, a paucity of culturally appropriate cancer health education programs for both Indigenous community members and health providers, and the historical absence of an Indigenous Australian focus and contribution to research on cancer causation. Indigenous Australian co-designed research is needed to address the gaps contributing to cancer prevention and screening development. Empowerment of national Indigenous Australian leadership in partnership with researchers and service providers is needed to develop tailored health interventions and reduce the existing and future challenges of the cancer burden on Indigenous communities.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101627"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From decentralization to re-centralization: lessons learned from Vietnam's rapid reversal in the financing of the Expanded Program on Immunization","authors":"Khanh Phuong Nguyen ,&nbsp;The Due Ong ,&nbsp;Xinyu Zhang ,&nbsp;Tra My Do ,&nbsp;Thi Quynh Trang Do ,&nbsp;Shenglan Tang","doi":"10.1016/j.lanwpc.2025.101648","DOIUrl":"10.1016/j.lanwpc.2025.101648","url":null,"abstract":"<div><div>Ensuring sufficient financial resources for improving effective and efficient procurement of vaccines was highlighted by the Immunization Agenda 2030, which is particularly challenging for middle-income countries (MICs) that are ineligible for support from Gavi, the Vaccine Alliance. In response to the broader decentralization of the governance system and decreased international development aid, the central government of Vietnam decentralized the responsibility of financing the Expanded Program on Immunization (EPI) to provincial governments in 2023 but rapidly reversed it considering its following negative consequences, for example, severe vaccine stockouts and the largest decline in childhood immunization coverage in over 20 years. This paper analyzed the consequences closely linked to decentralization in Vietnam, the underlying reasons, and lessons for other MICs. To avoid recurrence, MICs should ensure the primary role of the central government in EPI financing and management, improve the local management capacity, and allocate more resources toward less-developed areas to narrow the intra-country disparities.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101648"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient perspectives","authors":"Carmel R. Crook ,&nbsp;Sandra C. Thompson","doi":"10.1016/j.lanwpc.2025.101558","DOIUrl":"10.1016/j.lanwpc.2025.101558","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101558"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial","authors":"Qifa Liu ,&nbsp;Zhongli Hu ,&nbsp;Na Xu ,&nbsp;Yirong Jiang ,&nbsp;Zhiping Fan ,&nbsp;Fen Huang ,&nbsp;Ren Lin ,&nbsp;Hua Jin ,&nbsp;Yunxin Zeng ,&nbsp;Hai He ,&nbsp;Ping Zhu ,&nbsp;Guopan Yu ,&nbsp;Pengcheng Shi ,&nbsp;Ruijuan Sun ,&nbsp;Xiaojun Xu ,&nbsp;Zhangkun Li ,&nbsp;Yu Zhang ,&nbsp;Jing Sun ,&nbsp;Yu Wang ,&nbsp;Li Xuan","doi":"10.1016/j.lanwpc.2025.101664","DOIUrl":"10.1016/j.lanwpc.2025.101664","url":null,"abstract":"<div><h3>Background</h3><div>Outcomes of older patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT) remain unsatisfactory. The primary objective of this trial was to establish whether decitabine combined with reduced-intensity conditioning (RIC) regimen could improve overall survival (OS) for this population in composite complete remission (CRc).</div></div><div><h3>Methods</h3><div>We conducted a single-arm, phase 2 trial at six hospitals in China. Eligible patients were aged 60–80 years, had a diagnosis of AML, achieved CRc at transplantation, were willing to undergo the first allo-HSCT, and had an Eastern Cooperative Oncology Group performance status of 0–2. Patients received decitabine combined with RIC regimen, comprising decitabine 20 mg/m² daily intravenously (days −9 to −7), busulfan 3.2 mg/kg daily intravenously (days −5 to −4), and fludarabine 30 mg/m² daily intravenously (days −6 to −3). The primary endpoint was 2-year OS rate. All efficacy and safety endpoints were assessed in the intention-to-treat population. This trial is registered with <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (<span><span>NCT03530085</span><svg><path></path></svg></span>) and is complete.</div></div><div><h3>Findings</h3><div>Between Jan 1, 2021 and Nov 30, 2022, 60 patients were enrolled. With a median follow-up of 35.5 months (IQR 32.5–39.2), 39 patients survived and 21 died. The 2-year OS rate was 67% (95% CI 56–80), which met the primary objective. Within 100 days post-transplantation, the most common grade 3–4 non-hematological treatment-emergent adverse events (TEAEs) were infections (22 [37%]), acute graft-versus-host disease (21 [35%]), and gastrointestinal disorders (16 [27%]). Five (8%) patients died of TEAEs, with one death treatment-related.</div></div><div><h3>Interpretation</h3><div>Decitabine combined with RIC regimen exhibits encouraging OS and acceptable toxicity profile, which might be a suitable therapeutic option for older patients with AML.</div></div><div><h3>Funding</h3><div><span>National Natural Science Foundation of China</span>; <span>Science and Technology Program of Guangdong</span> Province; <span>National Key Research and Development Program of China</span>.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101664"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental health literacy and the stigmatisation and discrimination of individuals affected by mental illnesses in China: a scoping review","authors":"Yamin Zhang ,&nbsp;Meng Zhou ,&nbsp;Rong Liang ,&nbsp;Jingyuan Chen ,&nbsp;Puyu Shi ,&nbsp;Yanghao Zheng ,&nbsp;Xing Luo ,&nbsp;Yuejing Wu ,&nbsp;Xueli Yu ,&nbsp;You Wu ,&nbsp;Sugai Liang ,&nbsp;Wei Deng ,&nbsp;Marlys Ann Bueber ,&nbsp;Michael Robert Phillips ,&nbsp;Tao Li","doi":"10.1016/j.lanwpc.2025.101642","DOIUrl":"10.1016/j.lanwpc.2025.101642","url":null,"abstract":"<div><div>Low mental health literacy (MHL) could contribute to misconceptions about mental illnesses and reinforce various forms of stigma (public, personal, and associative), leading to discrimination, reduced help-seeking, and poorer mental health outcomes. To summarise the current state of the literature on MHL, stigma, and discrimination, this scoping review identified 387 studies published from 2000 to 2024 in five English and three Chinese databases: 60.7% focused on stigma, 31.8% on MHL, and only 7.5% on discrimination. Most studies (84.8%) were descriptive cross-sectional studies, 14.5% evaluated interventions, and 0.7% were non-intervention longitudinal studies. Methodological quality was generally low: reports about 88.4% of the cross-sectional studies, 75.6% of the randomised controlled trials, and 83.4% of the quasi-experimental studies lacked descriptions of key methodological or statistical details. After excluding researcher-developed tools only reported in a single study, 125 assessment tools remained, 26.4% of which were developed in China. Although 21 different mental health conditions were studied, 91.0% of the studies focused on a single condition. Study locations were geographically skewed (one-third of all studies were conducted in Guangdong, Beijing, and Shanghai), and study participants were not representative of the target cohort. The number of publications increased substantially after 2010. Most of the 56 intervention studies, which primarily used psychoeducational interventions, reported improved MHL and decreased stigma. Recommendations for future studies include: 1) Develop standardised instruments to improve comparability. 2) Ensure detailed statistical analyses and clearly defined sample characteristics. 3) Assess variations in MHL, stigmatisation, and discrimination across different mental health conditions. 4) Increase research in underserved regions and conduct nationwide longitudinal studies. 5) Include a broader range of participants in intervention studies and consider new intervention strategies (i.e., other than psychoeducation interventions). 6) Align research objectives with national mental health policies to enhance their relevance and impact.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"61 ","pages":"Article 101642"},"PeriodicalIF":8.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144912947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}